Breaking: Oxford Immunotec Global PLC on Focus After Trading At 52-Week Highs

Breaking: Oxford Immunotec Global PLC on Focus After Trading At 52 Week Highs

The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) hit a new 52-week high and has $27.70 target or 94.00% above today’s $14.28 share price. The 9 months bullish chart indicates low risk for the $334.80 million company. The 1-year high was reported on Nov, 7 by Barchart.com. If the $27.70 price target is reached, the company will be worth $314.71M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 2.37% or $0.33 on November 7, hitting $14.28. About 62,772 shares traded hands or 2.83% up from the average. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 29.65% since April 5, 2016 and is uptrending. It has outperformed by 27.69% the S&P500.

According to Zacks Investment Research, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom.”

Insitutional Activity: The institutional sentiment increased to 1.5 in Q2 2016. Its up 0.36, from 1.14 in 2016Q1. The ratio is positive, as 7 funds sold all Oxford Immunotec Global PLC shares owned while 13 reduced positions. 7 funds bought stakes while 23 increased positions. They now own 17.53 million shares or 3.01% less from 18.07 million shares in 2016Q1.
Nationwide Fund Advisors has 13,511 shares for 0% of their US portfolio. Cortina Asset Ltd Liability Corporation last reported 0.25% of its portfolio in the stock. Geode Mgmt Ltd Liability Corp holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 36,236 shares. Blackrock Fund Advisors, a California-based fund reported 574,157 shares. Moreover, Sg Americas Secs Ltd Liability Company has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 12,717 shares. Acuta Capital Partners Limited Liability Company holds 1.8% or 417,278 shares in its portfolio. Kornitzer Cap Mngmt Ks has invested 0.02% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Polar Cap Ltd Liability Partnership last reported 0.23% of its portfolio in the stock. Manufacturers Life Ins Company The has 0% invested in the company for 13,875 shares. Deerfield Mgmt, a New York-based fund reported 464,541 shares. Moreover, Birchview Capital Lp has 0.37% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 56,303 shares. Bank & Trust Of New York Mellon Corporation owns 51,899 shares or 0% of their US portfolio. Renaissance Ltd Limited Liability Company holds 126,800 shares or 0% of its portfolio. The Illinois-based Northern Tru has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Wall Street Associate last reported 22,800 shares in the company.

More important recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Seekingalpha.com which released: “Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q3 2016 Results …” on November 01, 2016, also Metrowestdailynews.com published article titled: “Oxford Immunotec Global PLC announces acquisition of Imugen Inc”, Quotes.Wsj.com published: “DOW JONES, A NEWS CORP COMPANY” on November 22, 2013. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) was released by: Streetinsider.com and their article: “Oxford Immunotec (OXFD) Acquires Immunetics in $12M Deal” with publication date: October 12, 2016.

OXFD Company Profile

Oxford Immunotec Global PLC, incorporated on August 16, 2013, is a global, commercial-stage diagnostics firm focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. The Company’s development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Through its early-stage immune-oncology program, it is investigating the use of its T-SPOT technology platform in cancer immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment